A practical reference on purity testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-21. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Homochirality is the uniformity of materials composed of chiral (non-mirror-symmetric) units. Living organisms use molecules with the same chirality: with almost no exceptions, amino acids are left-handed while nucleotides and sugars are right-handed. Chiral molecules can be synthesized, but in the absence of a chiral source or a chiral catalyst, they are formed in a 50/50 (racemic) mixture of both forms. Non-racemic mixtures can arise from racemic materials by asymmetric physical laws such as the electroweak interaction, or in asymmetric environments, such as those in which molecules are exposed to circularly polarized light of a given handedness. It has been hypothesized that the solar nebula was such an environment, exposed to circularly-polarized radiation from an external source before or during the epoch of planet formation. This proposal is consistent with the finding that some amino acids delivered to Earth in meteorites exhibit a chiral asymmetry of the same sign as terrestrial life. Once established, a chirality imbalance may influence subsequent chemical evolution. A small bias in the population can be amplified by asymmetric autocatalysis, as in the Soai reaction, where a chiral molecule catalyzes its own production.
=== Mechanism of elastic recoil === The characterization of disorder is consistent with an entropy-driven mechanism of elastic recoil. It is concluded that conformational disorder is a constitutive feature of elastin structure and function.
Chitosan is a deacetylated derivative of chitin. When the acetylated composition of the copolymer is below 50% it is chitosan. Chitosan is a semicrystalline "polymer of β-(1-4)-2-amino-2-deoxy-D-glucose". One difference between chitin and chitosan is that chitosan is soluble in acidic aqueous solutions. Chitosan is easier to process that chitin, but it is less stable because it is more hydrophilic and has pH sensitivity. Due to its ease of processing, chitosan is used in biomedical applications.
The articular cartilage function is dependent on the molecular composition of the extracellular matrix (ECM). The ECM consists mainly of proteoglycan and collagens. The main proteoglycan in cartilage is aggrecan, which, as its name suggests, forms large aggregates with hyaluronan and with itself. These aggregates are negatively charged and hold water in the tissue. The collagen, mostly collagen type II, constrains the proteoglycans. The ECM responds to tensile and compressive forces that are experienced by the cartilage. Cartilage growth thus refers to the matrix deposition, but can also refer to both the growth and remodeling of the extracellular matrix. Due to the great stress on the patellofemoral joint during resisted knee extension, the articular cartilage of the patella is among the thickest in the human body. The ECM of articular cartilage is classified into three regions: the pericellular matrix, the territorial matrix, and the interterritorial matrix.
Sources: en.wikipedia.org
On 3 January 2022, Hangman's Chair appeared on the Culturebox program on France 4. A Loner was released in February 2022. The band released the single "Who Wants To Die Old" alongside a music video directed by Oscar Bizarre, filmed before "Cold & Distant". A piece was finally performed by the pairing of Hangman's Chair and Regarde Les Hommes Tomber at the Roadburn Festival 2022 in Tilburg, Netherlands. On 23 June 2022, Arte Concert and Rolling Stone France teamed up to broadcast live the band's performance at Hellfest on YouTube. On 26 June, Hangman's Chair collaborated once again with the Nantes-based band Regarde Les Hommes Tomber for a concert on the Valley stage at Hellfest. The band performed at Les Francofolies in La Rochelle, France, and at other music festivals, and toured for five weeks with Paradise Lost. Hangman's Chair were ranked first in the "Best French Bands/Artists" category on the editorial board's year-end list of Guitar Part, a French monthly print magazine aimed at guitarists. Before embarking on a European tour with Igorrr, they presented a previously unreleased track, the six-minute single "Spleenwise", in March 2023. In 2023, Hangman's Chair were encouraged by their label to release a short, three-minute documentary titled A Portrait, directed by Kendy Ty, in which the band members recount their career and the A Loner era in a condensed and introspective way. For the documentary, the musicians returned to their neighbourhood, the school, and the playground where they grew up. In July 2023, the band performed at the Dour Festival in Belgium.
Several former employees of the company have claimed of poor workplace conditions, including the start of the workweek on Sunday to cooperate with Chinese time zones and excessive workload. Employees claimed they averaged 85 hours of meetings per week and would frequently stay up all night in order to complete tasks. Some employees claimed the workplace's schedule operated similarly to the 996 schedule. The company has a stated policy of working from 10 AM to 7 PM five days per week (63 hours per week), but employees noted that it was encouraged for employees to work after hours. One female worker complained that the company did not allow her adequate time to change her feminine hygiene product because of back-to-back meetings. Another employee noted that working at the company caused her to seek marriage therapy and lose an unhealthy amount of weight. In response to the allegations, the company noted that they were committed to allowing employees "support and flexibility". In September 2023, two former ByteDance employees filed a formal complaint with the US Equal Employment Opportunity Commission (EEOC) asking the EEOC to investigate TikTok's practice of retaliation against workers who complain about discrimination.
Late-stage functionalization (LSF) is a desired, chemical or biochemical, chemoselective transformation on a complex molecule to provide at least one analog in sufficient quantity and purity for a given purpose without needing the addition of a functional group that exclusively serves to enable said transformation. Molecular complexity is an intrinsic property of each molecule and frequently determines the synthetic effort to make it. LSF can significantly diminish this synthetic effort, and thus enables access to molecules, which would otherwise not be available or too difficult to access. The requirements for LSF can be met by both C–H functionalization reactions and functional group manipulations. LSF reactions are particularly relevant and often used in the fields of drug discovery and materials chemistry, although no LSF has been implemented in a commercial process.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.